Biopharmaceutical company Prota Therapeutics has announced its research, in partnership with Murdoch Children’s Research Institute (MCRI), has been awarded a prize at the European Academy of Allergy and Clinical Immunology (EAACI) for outstanding oral abstract presentation. 

The presentation reported three-year post-treatment findings from the Phase IIb PPOIT-003 long-term (PPOIT-003LT) study of Prota’s lead candidate, PRT120, a peanut oral immunotherapy with a proprietary short-term dosing regimen designed to induce durable remission. 

According to Professor Mimi Tang, Director of the Allergy Translation Centre and Head of Allergy Immunology at MCRI, and Scientific founder of Prota Therapeutics, the data from the study “reinforce remission as the preferred treatment outcome.” 

“Children in remission after Prota’s unique short-duration oral immunotherapy and dosing regimen, PRT120, not only maintain protection without daily dosing, but also enjoy a better quality of life and freedom from ongoing treatment burden,” Tang continued. “This work has only been possible through the collaborative efforts of the study teams at MCRI Allergy Immunology, Perth Children’s Hospital, and Adelaide Women’s and Children’s Hospital, and we are deeply grateful to the many families who participated in our trial.” 

In the study, at two years after stopping treatment, more than 95% of children who achieved remission were consuming peanuts freely or maintaining regular ingestion. At three years post-treatment, the longest follow-up reported to date, more than 90% of remission participants still in the study continued to eat peanuts regularly, with no moderate or severe reactions and no use of rescue epinephrine.  

Remission is a ‘durable’ endpoint 

Study participants who were desensitised without remission struggled to maintain daily ingestion, were more likely to stop treatment altogether, and continued to report moderate or severe reactions, including some that required epinephrine treatment. These results reinforce remission as the optimal endpoint for patients, provide a strong foundation for the upcoming four- and five-year analyses, and validate Prota’s plans to advance PRT120 into a Phase III clinical trial in the US, expected next year. 

“This recognition from EAACI underscores the clinical importance of remission as an endpoint,” added Paxton Loke, Research Clinician at MCRI and Principal Investigator for the PPOIT-003LT, who presented the data. “To see children remain protected and able to eat peanuts freely three years after completing PRT120 treatment, without the anxiety of significant reactions or the demands of indefinite dosing, demonstrates the potential of this approach to transform care for peanut allergy.” 

The recognition at EAACI, the leading professional society for allergy and clinical immunology in Europe, affirms the scientific significance of remission as a durable and clinically meaningful endpoint. It follows a 2023 award at the GALEN GA²FA Annual Conference for Prota’s and MCRI’s two-year post-treatment outcomes, marking consecutive international recognition of the program’s long-term data. 

“While these awards are not formal measures of clinical success, they do reflect meaningful acknowledgment from leading scientific forums,” Tang added. “Importantly, they provide a strong foundation for our upcoming four- to five-year analyses, which continue to show persistence of remission and sustained improvements in quality of life – rare achievements in the food allergy space.” 

 

 

 Bruno Quinney, Content Team, DDW